India, Sept. 16 -- Biodexa Pharmaceutical PLC (BDRX), a clinical-stage biopharmaceutical company, on Wednesday reported entering a warrant exercise agreement with an accredited investor to exercise outstanding warrants for an aggregate of 2,204,218 American Depositary Shares (ADSs).
The company is offering exercising holders new unregistered warrants to purchase up to 4,408,436 ADSs in consideration of the immediate exercise of existing warrants. The new warrants will have an exercise price of $1.50, with a term of exercise amounting to five years from the time of issuance.
The warrant inducement transaction is anticipated to close on September 15, 2026.
Gross proceeds from the transaction are estimated to be $2.3 million.
Recently, the...